Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Monday

Aligos Therapeutics (NASDAQ:ALGS) will likely be posting its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($2.09) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

Aligos Therapeutics Trading Down 6.3%

Shares of Aligos Therapeutics stock opened at $7.03 on Monday. Aligos Therapeutics has a twelve month low of $3.76 and a twelve month high of $17.39. The stock has a market cap of $43.23 million, a price-to-earnings ratio of -0.36 and a beta of 2.67. The company has a fifty day moving average price of $8.23 and a 200 day moving average price of $9.13.

Analyst Ratings Changes

Several brokerages have recently weighed in on ALGS. UBS Group started coverage on Aligos Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $35.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new stake in Aligos Therapeutics during the 3rd quarter valued at approximately $99,000. XTX Topco Ltd purchased a new position in shares of Aligos Therapeutics during the 2nd quarter valued at approximately $100,000. HRT Financial LP purchased a new position in shares of Aligos Therapeutics during the 4th quarter valued at approximately $106,000. DRW Securities LLC acquired a new stake in shares of Aligos Therapeutics during the fourth quarter worth approximately $111,000. Finally, Jane Street Group LLC bought a new stake in shares of Aligos Therapeutics in the fourth quarter worth $226,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.